Does an Autoimmune Disorder Following Ovarian Cancer Diagnosis Affect Prognosis?
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Population
2.2. Outcome Measures
2.3. Statistical Analysis
3. Results
3.1. Primary Analysis (Two-Group Comparison)
3.2. Secondary Analysis (Three-Group Comparison)
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Momenimovahed, Z.; Tiznobaik, A.; Taheri, S.; Salehiniya, H. Ovarian Cancer in the World: Epidemiology and Risk Factors. Int. J. Womens Health 2019, 11, 287–299. [Google Scholar] [CrossRef] [PubMed]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- González-Martín, A.; Harter, P.; Leary, A.; Lorusso, D.; Miller, R.E.; Pothuri, B.; Ray-Coquard, I.; Tan, D.S.P.; Bellet, E.; Oaknin, A.; et al. Newly Diagnosed and Relapsed Epithelial Ovarian Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2023, 34, 833–848. [Google Scholar] [CrossRef]
- Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Mortality—All COD, Aggregated with State, Total U.S. (1969–2020) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Released September 2022. Underlying Mortality Data Provided by NCHS. Available online: www.cdc.gov/nchs (accessed on 25 June 2024).
- González-Martín, A.; Pothuri, B.; Vergote, I.; DePont Christensen, R.; Graybill, W.; Mirza, M.R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 2019, 381, 2391–2402. [Google Scholar] [CrossRef]
- Pujade-Lauraine, E.; Hilpert, F.; Weber, B.; Reuss, A.; Poveda, A.; Kristensen, G.; Sorio, R.; Vergote, I.; Witteveen, P.; Bamias, A.; et al. Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. J. Clin. Oncol. 2014, 32, 1302–1308. [Google Scholar] [CrossRef] [PubMed]
- Oza, A.M.; Cook, A.D.; Pfisterer, J.; Embleton, A.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; et al. Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial. Lancet Oncol. 2015, 16, 928–936. [Google Scholar] [CrossRef] [PubMed]
- Marth, C.; Abreu, M.H.; Andersen, K.K.; Aro, K.M.; De Lurdes Batarda, M.; Boll, D.; Ekmann-Gade, A.W.; Haltia, U.; Hansen, J.; Haug, A.J.; et al. Real-life Data on Treatment and Outcomes in Advanced Ovarian Cancer: An Observational, Multinational Cohort Study (RESPONSE Trial). Cancer 2022, 128, 3080–3089. [Google Scholar] [CrossRef] [PubMed]
- Mirza, M.R.; Coleman, R.L.; González-Martín, A.; Moore, K.N.; Colombo, N.; Ray-Coquard, I.; Pignata, S. The Forefront of Ovarian Cancer Therapy: Update on PARP Inhibitors. Ann. Oncol. 2020, 31, 1148–1159. [Google Scholar] [CrossRef] [PubMed]
- Perren, T.J.; Swart, A.M.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; Kurzeder, C.; et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N. Engl. J. Med. 2011, 365, 2484–2496. [Google Scholar] [CrossRef]
- Burger, R.A.; Brady, M.F.; Bookman, M.A.; Fleming, G.F.; Monk, B.J.; Huang, H.; Mannel, R.S.; Homesley, H.D.; Fowler, J.; Greer, B.E.; et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N. Engl. J. Med. 2011, 365, 2473–2483. [Google Scholar] [CrossRef]
- Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V. (DGGG) S3-Leitlinie Diagnostik, Therapie und Nachsorge Maligner Ovarialtumoren 2022. Available online: https://awmf.org (accessed on 25 June 2024).
- Liu, S.; Wu, M.; Wang, F. Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer. J. Cancer 2021, 12, 3976–3996. [Google Scholar] [CrossRef] [PubMed]
- Curiel, T.J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J.R.; Zhang, L.; Burow, M.; et al. Specific Recruitment of Regulatory T Cells in Ovarian Carcinoma Fosters Immune Privilege and Predicts Reduced Survival. Nat. Med. 2004, 10, 942–949. [Google Scholar] [CrossRef]
- Li, J.; Wang, J.; Chen, R.; Bai, Y.; Lu, X. The Prognostic Value of Tumor-Infiltrating T Lymphocytes in Ovarian Cancer. Oncotarget 2017, 8, 15621–15631. [Google Scholar] [CrossRef]
- Ovarian Tumor Tissue Analysis (OTTA) Consortium; Goode, E.L.; Block, M.S.; Kalli, K.R.; Vierkant, R.A.; Chen, W.; Fogarty, Z.C.; Gentry-Maharaj, A.; Toloczko, A.; Hein, A.; et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 2017, 3, e173290. [Google Scholar] [CrossRef] [PubMed]
- Hamanishi, J.; Mandai, M.; Ikeda, T.; Minami, M.; Kawaguchi, A.; Murayama, T.; Kanai, M.; Mori, Y.; Matsumoto, S.; Chikuma, S.; et al. Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients with Platinum-Resistant Ovarian Cancer. J. Clin. Oncol. 2015, 33, 4015–4022. [Google Scholar] [CrossRef] [PubMed]
- Matulonis, U.A.; Shapira-Frommer, R.; Santin, A.; Lisyanskaya, A.S.; Pignata, S.; Vergote, I.; Raspagliesi, F.; Sonke, G.S.; Birrer, M.; Provencher, D.M.; et al. Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Interim Results from the Phase 2 KEYNOTE-100 Study. J. Clin. Oncol. 2018, 36, 5511. [Google Scholar] [CrossRef]
- Varga, A.; Piha-Paul, S.; Ott, P.A.; Mehnert, J.M.; Berton-Rigaud, D.; Morosky, A.; Yang, P.; Ruman, J.; Matei, D. Pembrolizumab in Patients with Programmed Death Ligand 1-Positive Advanced Ovarian Cancer: Analysis of KEYNOTE-028. Gynecol. Oncol. 2019, 152, 243–250. [Google Scholar] [CrossRef]
- Pujade-Lauraine, E.; Fujiwara, K.; Ledermann, J.A.; Oza, A.M.; Kristeleit, R.; Ray-Coquard, I.-L.; Richardson, G.E.; Sessa, C.; Yonemori, K.; Banerjee, S.; et al. Avelumab Alone or in Combination with Chemotherapy versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study. Lancet Oncol. 2021, 22, 1034–1046. [Google Scholar] [CrossRef]
- Monk, B.J.; Colombo, N.; Oza, A.M.; Fujiwara, K.; Birrer, M.J.; Randall, L.; Poddubskaya, E.V.; Scambia, G.; Shparyk, Y.V.; Lim, M.C.; et al. Chemotherapy with or without Avelumab Followed by Avelumab Maintenance versus Chemotherapy Alone in Patients with Previously Untreated Epithelial Ovarian Cancer (JAVELIN Ovarian 100): An Open-Label, Randomised, Phase 3 Trial. Lancet Oncol. 2021, 22, 1275–1289. [Google Scholar] [CrossRef]
- Duranti, S.; Pietragalla, A.; Daniele, G.; Nero, C.; Ciccarone, F.; Scambia, G.; Lorusso, D. Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data. Cancers 2021, 13, 2089. [Google Scholar] [CrossRef]
- Fucikova, J.; Coosemans, A.; Orsulic, S.; Cibula, D.; Vergote, I.; Galluzzi, L.; Spisek, R. Immunological Configuration of Ovarian Carcinoma: Features and Impact on Disease Outcome. J. Immunother. Cancer 2021, 9, e002873. [Google Scholar] [CrossRef] [PubMed]
- Oaknin, A.; Bosse, T.J.; Creutzberg, C.L.; Giornelli, G.; Harter, P.; Joly, F.; Lorusso, D.; Marth, C.; Makker, V.; Mirza, M.R.; et al. Endometrial Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2022, 33, 860–877. [Google Scholar] [CrossRef] [PubMed]
- Kurtz, J.-E.; Pujade-Lauraine, E.; Oaknin, A.; Belin, L.; Leitner, K.; Cibula, D.; Denys, H.; Rosengarten, O.; Rodrigues, M.; De Gregorio, N.; et al. Atezolizumab Combined with Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-Ov29 Trial. J. Clin. Oncol. 2023, 41, 4768–4778. [Google Scholar] [CrossRef] [PubMed]
- Brodeur, M.N.; Dopeso, H.; Zhu, Y.; Longhini, A.L.F.; Gazzo, A.; Sun, S.; Koche, R.; Qu, R.; Hamard, P.-J.; Bykov, Y.; et al. Interferon Response and Epigenetic Modulation by SMARCA4 Mutations Drive Ovarian Tumor Immunogenicity. bioRxiv 2023. [Google Scholar] [CrossRef]
- Conrad, N.; Misra, S.; Verbakel, J.Y.; Verbeke, G.; Molenberghs, G.; Taylor, P.N.; Mason, J.; Sattar, N.; McMurray, J.J.V.; McInnes, I.B.; et al. Incidence, Prevalence, and Co-Occurrence of Autoimmune Disorders over Time and by Age, Sex, and Socioeconomic Status: A Population-Based Cohort Study of 22 Million Individuals in the UK. Lancet 2023, 401, 1878–1890. [Google Scholar] [CrossRef]
- Hannibal, C.G.; Kjaer, S.K.; Galanakis, M.; Hertzum-Larsen, R.; Maltesen, T.; Baandrup, L. History of Autoimmune Disease and Long-Term Survival of Epithelial Ovarian Cancer: The Extreme Study. Gynecol. Oncol. 2024, 182, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Dedousis, D.; Zhang, A.L.; Vassiliou, A.N.; Cao, S.; Yammani, D.; Kyasaram, R.K.; Shanahan, J.P.; Keinath, M.C.; Hsu, M.L.; Fu, P.; et al. Survival in Elderly Patients with Breast Cancer with and without Autoimmune Disease. Cancer Med. 2023, 12, 13086–13099. [Google Scholar] [CrossRef] [PubMed]
- Wouters, R.; Vankerckhoven, A.; Verreet, W.; Ceusters, J.; Coosemans, A. Do Autoimmune Diseases Influence the Onset and Progression of Ovarian Cancer? A Systematic Review and Meta-Analysis. Int. J. Gynecol. Cancer 2022, 32, 1583–1591. [Google Scholar] [CrossRef] [PubMed]
- Bagchi, S.; Yuan, R.; Engleman, E.G. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu. Rev. Pathol. Mech. Dis. 2021, 16, 223–249. [Google Scholar] [CrossRef]
- Du, Y.; Wu, W.; Chen, M.; Dong, Z.; Wang, F. Cutaneous Adverse Events and Cancer Survival Prognosis with Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis. JAMA Dermatol. 2023, 159, 1093–1101. [Google Scholar] [CrossRef]
- Zhong, L.; Wu, Q.; Chen, F.; Liu, J.; Xie, X. Immune-Related Adverse Events: Promising Predictors for Efficacy of Immune Checkpoint Inhibitors. Cancer Immunol. Immunother. 2021, 70, 2559–2576. [Google Scholar] [CrossRef] [PubMed]
- Jacoby, T.V.; Shah, N.; Asdourian, M.S.; Thompson, L.L.; Otto, T.S.; LeBoeuf, N.R.; Semenov, Y.; Dee, E.C.; Reynolds, K.L.; Chen, S.T. Dermatology Evaluation for Cutaneous Immune-Related Adverse Events Is Associated with Improved Survival in Cancer Patients Treated with Checkpoint Inhibition. J. Am. Acad. Dermatol. 2023, 88, 711–714. [Google Scholar] [CrossRef] [PubMed]
- Gill, A.; Gosain, R.; Bhandari, S.; Gosain, R.; Gill, G.; Abraham, J.; Miller, K. “Lost to Follow-up” among Adult Cancer Survivors. Am. J. Clin. Oncol. 2018, 41, 1024–1027. [Google Scholar] [CrossRef] [PubMed]
Parameters | No AID Ever | AID before Cancer Diagnosis | AID after Cancer Diagnosis | p-Value ** | |||
---|---|---|---|---|---|---|---|
Total (n = 128) | n = 110 | n = 9 | n = 9 | -- | |||
Age at cancer diagnosis (mean, standard deviation) | 65.5 | ±10 | 62.8 | ±11 | 65 | ±6 | 0.246 |
Body mass index-kg/m2 (median, IQR) | 25 | 22–28 | 23 | 23–26 | 27 | 23–28 | 0.641 |
Race (white) * | 108 | 98% | 9 | 100% | 9 | 100% | 0.999 |
Smoker (yes) | 11 | 10% | 1 | 11% | 1 | 11% | 0.999 |
BRCA mutation (yes) | 12 | 11% | 2 | 22% | 2 | 22% | 0.048 |
Histologic subtype | 0.7556 | ||||||
Serous | 102 | 93% | 8 | 89% | 9 | 100% | |
Endometrioid | 7 | 6% | 1 | 11% | 0 | -- | |
Transitional cell | 1 | 1% | 0 | -- | 0 | -- | |
No residual tumor (R0) | 44 | 40% | 4 | 44% | 6 | 67% | 0.321 |
Nodal status * | 0.413 | ||||||
pN0 | 36 | 34% | 4 | 44% | 5 | 56% | |
pN1 | 70 | 66% | 5 | 56% | 4 | 44% | |
FIGO | 0.76 | ||||||
III | 80 | 74% | 6 | 67% | 6 | 67% | |
IV | 30 | 26% | 3 | 33% | 3 | 33% | |
Cycles of primary chemotherapy † (median, range) | 6 | 1–6 | 6 | 5–6 | 6 | 6–6 | 0.837 |
First-line maintenance therapy (yes) | 65 | 59% | 7 | 78% | 7 | 78% | 0.324 |
Treatments for recurrence (median, range) | 2 | 1–9 | 2 | 1–3 | 2.5 | 2–3 | 0.7018 |
Survival time in days (median, IQR) | 932 | 567–1846 | 1093 | 716–1705 | 3031 | 1765–3963 | 0.0042 |
No evidence of disease at last follow-up (yes) | 9 | 8% | 1 | 11% | 4 | 44% | 0.012 |
Case | Age (Years) | FIGO Stage | Residual Tumor | BRCA 1/2 Mutation | Maintenance Therapy | Autoimmune Disorder | Time to Disease * | Autoimmune Disorder Therapy | Recurrences (Number) | Survival Status | Survival Time (Days) |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 72 | III | R1 | Unknown | Bevacizumab | Polymyalgia rheumatica | 5 years | Prednisone | 0 | Alive | 3716 |
2 | 64 | IV | R0 | Negative | Bevacizumab, niraparib | Rheumatoid arthritis | 4 years | Etanercept, methotrexate | 3 | Alive | 4290 |
3 | 67 | III | R2 | Negative | Bevacizumab | Granulomatosis with polyangiitis (Wegener’s disease) | 2 years | Methotrexate | 2 | Died | 1765 |
4 | 63 | IV | R0 | Unknown | -- | Chronic lymphocytic leukemia with prurigo nodularis | 6 years | Corticosteroid (local) | 0 | Alive | 4443 |
5 | 57 | III | R0 | Negative | Bevacizumab, niraparib | Rheumatoid arthritis | 2 years | Prednisone, methotrexate | 2 | Alive | 1627 |
6 | 67 | IV | R1 | Positive | Olaparib | Systemic lupus erythematosus | 5 years | Corticosteroid (local) | 3 | Alive | 3031 |
7 | 76 | III | R0 | Negative | Bevacizumab | Rheumatoid arthritis | 2 years | Prednisone | 0 | Alive | 1930 |
8 | 58 | III | R0 | Negative | -- | Dermatomyositis | 1 year | Prednisone, methotrexate, hydroxychloroquine, mycophenolic acid, rituximab, corticosteroid (local) | 0 | Alive | 3963 |
9 | 60 | III | R0 | Positive | Olaparib | Leukocytoclastic vasculitis | 1.5 years | Prednisone, enoxaparin | 0 | Alive | 747 |
Case | Age (Years) | FIGO Stage | Residual Tumor | BRCA 1/2 Mutation | Maintenance Therapy | Autoimmune Disorder | Time to Disease * | Autoimmune Disorder Therapy | Recurrences (Number) | Survival Status | Survival Time (Days) |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 76 | III | R2 | Negative | Bevacizumab | Rheumatoid arthritis | Unknown † | Methotrexate, deflazacort | 1 | Died | 806 |
2 | 69 | IV | R2 | Negative | Bevacizumab, olaparib | Polymyalgia rheumatica | 11 years | Prednisone | 2 | Alive | 676 |
3 | 65 | IV | R2 | Negative | Bevacizumab, olaparib | Rheumatoid arthritis | 2 months | Unknown † | 3 | Died | 716 |
4 | 51 | III | R2 | Positive | Bevacizumab, olaparib | Systemic lupus erythematosus | 2 years | Hydroxychoroquine, prednisone | 3 | Died | 1705 |
5 | 75 | IV | R0 | Unknown | Bevacizumab | Chronic lymphocytic leukemia with immune thrombocytopenia | 15 years | Rituximab, bendamustine, prednisone | 1 | Died | 1093 |
6 | 67 | III | R0 | Negative | Bevacizumab | Ankylosing spondylitis (Bechterew’s disease) | Unknown † | Local steroids | 1 | Died | 1206 |
7 | 61 | III | R0 | Negative | -- | Ulcerative colitis | 7 years | Mesalazine | 2 | Alive | 2869 |
8 | 59 | III | R0 | Negative | Bevacizumab, olaparib | Mixed connective tissue disease | 3 years | Hydroxychloroquine, prednisone, sulfasalazine, methotrexate, cyclophosphamide, rituximab | 2 | Alive | 538 |
9 | 42 | III | R2 | Positive | -- | Autoimmune diabetes mellitus (Type 1) | 3 years | Insulin detemir, insulin aspart | 3 | Died | 1819 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fröhlich, A.; Welter, J.; Witzel, I.; Voppichler, J.; Fehr, M.K. Does an Autoimmune Disorder Following Ovarian Cancer Diagnosis Affect Prognosis? Curr. Oncol. 2024, 31, 4613-4623. https://doi.org/10.3390/curroncol31080344
Fröhlich A, Welter J, Witzel I, Voppichler J, Fehr MK. Does an Autoimmune Disorder Following Ovarian Cancer Diagnosis Affect Prognosis? Current Oncology. 2024; 31(8):4613-4623. https://doi.org/10.3390/curroncol31080344
Chicago/Turabian StyleFröhlich, Anaïs, JoEllen Welter, Isabell Witzel, Julia Voppichler, and Mathias K. Fehr. 2024. "Does an Autoimmune Disorder Following Ovarian Cancer Diagnosis Affect Prognosis?" Current Oncology 31, no. 8: 4613-4623. https://doi.org/10.3390/curroncol31080344